Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks children 6 – 11 years old with chronic hepatitis C infection

Trial Profile

Safety and efficacy of Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks children 6 – 11 years old with chronic hepatitis C infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2018 Status changed from recruiting to completed as per the results.
    • 02 Aug 2018 Results assessing the safety and efficacy (n=92, median age=9 years) published in the Hepatology.
    • 07 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top